Generic Thalomid Availability

Thalomid is a brand name of thalidomide, approved by the FDA in the following formulation(s):

THALOMID (thalidomide - capsule;oral)

  • Manufacturer: CELGENE
    Approval date: July 16, 1998
    Strength(s): 50MG
  • Manufacturer: CELGENE
    Approval date: January 17, 2003
    Strength(s): 100MG, 200MG [RLD]
  • Manufacturer: CELGENE
    Approval date: January 10, 2007
    Strength(s): 150MG

Has a generic version of Thalomid been approved?

No. There is currently no therapeutically equivalent version of Thalomid available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Thalomid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods and compositions for inhibition of angiogenesis
    Patent 5,629,327
    Issued: May 13, 1997
    Inventor(s): D'Amato; Robert
    Assignee(s): Childrens Hospital Medical Center Corp.
    The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Patent expiration dates:
    • May 13, 2014
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 6,045,501
    Issued: April 4, 2000
    Inventor(s): Elsayed; Marc & Williams; Bruce
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    • August 28, 2018
      ✓ 
      Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
  • Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
    Patent 6,315,720
    Issued: November 13, 2001
    Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
    Assignee(s): Celgene Corporation
    Improved methods for delivering to a patient in need of the drug, while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug are disclosed. The methods are of the type in which prescriptions for the drug are filled only after a computer readable storage medium has been consulted to assure that the prescriber, pharmacy and patient have been properly registered in the medium before the patient is approved to receive the drug. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to the side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    • October 23, 2020
      ✓ 
      Patent use: METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 6,561,976
    Issued: May 13, 2003
    Inventor(s): Marc; Elsayed & Bruce; Williams
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    • August 28, 2018
      ✓ 
      Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 6,561,977
    Issued: May 13, 2003
    Inventor(s): Bruce A.; Williams & Joseph K.; Kaminski
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    • October 23, 2020
      ✓ 
      Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 6,755,784
    Issued: June 29, 2004
    Inventor(s): Bruce A.; Williams & Joseph K.; Kaminski
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    • October 23, 2020
      ✓ 
      Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 6,869,399
    Issued: March 22, 2005
    Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    • October 23, 2020
      ✓ 
      Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
    • October 23, 2020
      ✓ 
      Patent use: MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
    • October 23, 2020
      ✓ 
      Patent use: ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 6,908,432
    Issued: June 21, 2005
    Inventor(s): Elsayed; Marc & Williams; Bruce
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    • August 28, 2018
      ✓ 
      Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 7,141,018
    Issued: November 28, 2006
    Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    • October 23, 2020
      ✓ 
      Patent use: MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
    • October 23, 2020
      ✓ 
      Patent use: ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
    • October 23, 2020
      ✓ 
      Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
  • Pharmaceutical compositions and dosage forms of thalidomide
    Patent 7,230,012
    Issued: June 12, 2007
    Inventor(s): D'Angio; Paul & McCarty; John
    Assignee(s): Celgene Corporation
    Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
    Patent expiration dates:
    • December 9, 2023
      ✓ 
      Drug product
  • Methods and compositions for inhibition of angiogenesis
    Patent 7,435,745
    Issued: October 14, 2008
    Inventor(s): D'Amato; Robert J.
    Assignee(s): Celgene Corporation
    The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
    Patent expiration dates:
    • November 3, 2017
      ✓ 
      Patent use: USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 7,874,984
    Issued: January 25, 2011
    Inventor(s): Elsayed; Marc & Williams; Bruce
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
    • August 28, 2018
      ✓ 
      Patent use: TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
    • August 28, 2018
      ✓ 
      Patent use: MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
    • August 28, 2018
      ✓ 
      Patent use: ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
    • August 28, 2018
      ✓ 
      Patent use: METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 7,959,566
    Issued: June 14, 2011
    Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 8,204,763
    Issued: June 19, 2012
    Inventor(s): Elsayed; Marc & Williams; Bruce
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 8,315,886
    Issued: November 20, 2012
    Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 8,589,188
    Issued: November 19, 2013
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a fetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to fetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 8,626,531
    Issued: January 7, 2014
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)